Oculis Holding AG (OCS) Other Non-Current Liabilities (2023 - 2026)
Oculis Holding AG's (OCS) quarterly Other Non-Current Liabilities came in at $26.2 million in Q1 2026, up 57.89% year-on-year from $16.6 million in Q1 2025, and up 44.81% quarter-over-quarter from $18.1 million in Q4 2025.
Oculis Holding AG (OCS) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Oculis Holding AG's Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $26.2 million for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 57.89% year-over-year to $26.2 million in Q1 2026; TTM through Mar 2026 was $26.2 million, a 57.89% increase from a year earlier, with the FY2025 full-year figure at $17.5 million, down 22.61% from the prior year.
- Other Non-Current Liabilities advanced to $26.2 million in Q1 2026 per OCS's latest filing, from $18.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $26.2 million in Q1 2026 and bottomed at $4.8 million in Q2 2023.
- The 4-year median for Other Non-Current Liabilities is $12.4 million (2025), against an average of $13.5 million.
- Across the five-year window, Other Non-Current Liabilities surged 274.31% in 2024 and decreased 20.06% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $6.1 million in 2023, then jumped by 274.31% to $22.7 million in 2024, then fell by 20.06% to $18.1 million in 2025, then surged by 44.81% to $26.2 million in 2026.
- Per Business Quant, the three latest OCS Other Non-Current Liabilities figures stand at $26.2 million (Q1 2026), $18.1 million (Q4 2025), and $15.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.23 Mn |
| Dec 31, 2025 | 18.11 Mn |
| Sep 30, 2025 | 15.18 Mn |
| Jun 30, 2025 | 18.25 Mn |
| Mar 31, 2025 | 16.61 Mn |
| Dec 31, 2024 | 22.66 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 8.14 Mn |
| Mar 31, 2024 | 9.67 Mn |
| Dec 31, 2023 | 6.05 Mn |
| Sep 30, 2023 | 7.45 Mn |
| Jun 30, 2023 | 4.78 Mn |